NCT00813826

Efficacy and Safety Study of SLC022 in Treating Pain Associated With Post Herpetic Neuralgia

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Tolerability of Oral SLC022 300 mg TID, a Glial Cell Modulating Agent, Versus Placebo in the Treatment of Post Herpetic Neuralgia

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 204 (estimated)
• Sponsor: Solace Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of SLC022 in treating pain associated with post-herpetic neuralgia (PHN) in recently diagnosed patients.

Detailed description

This study will enroll subjects with established PHN, a stable pain intensity and that meet all other eligibility criteria.

Conditions

• Postherpetic Neuralgia

Interventions

Type	Name	Description
DRUG	SLC022	SLC022 150 mg capsule, 900mg daily dose
DRUG	Placebo	Placebo capsule, TID

Timeline

• Start date: 2009-01-01
• Primary completion: 2009-10-01
• Completion: 2009-11-01
• First posted: 2008-12-23
• Last updated: 2009-07-30

Locations

19 sites across 1 country: United States